Total Payments
$972,713
2024 Payments
$97,795
Companies
69
Transactions
2,462
Medicare Patients
11,186
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$830,702 (85.4%)
Travel$66,178 (6.8%)
Food & Beverage$37,220 (3.8%)
Consulting$37,126 (3.8%)
Research$1,259 (0.1%)
Gifts$118.80 (0.0%)
Education$109.84 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $817,018 | 713 | 84.0% |
| Travel and Lodging | $66,178 | 235 | 6.8% |
| Food and Beverage | $37,220 | 1,468 | 3.8% |
| Consulting Fee | $37,126 | 24 | 3.8% |
| Honoraria | $13,684 | 9 | 1.4% |
| Unspecified | $1,259 | 1 | 0.1% |
| Gift | $118.80 | 2 | 0.0% |
| Education | $109.84 | 10 | 0.0% |
Payments by Type
General
$971,454
2,461 transactions
Research
$1,259
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $391,899 | 649 | $0 (2024) |
| Novo Nordisk Inc | $209,812 | 331 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $194,219 | 329 | $0 (2024) |
| Tandem Diabetes Care, Inc. | $38,274 | 149 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $37,802 | 100 | $0 (2020) |
| Xeris Pharmaceuticals, Inc. | $26,853 | 114 | $0 (2024) |
| Corcept Therapeutics | $23,891 | 57 | $0 (2023) |
| Merck Sharp & Dohme LLC | $18,025 | 83 | $0 (2023) |
| IBSA Pharma Inc. | $8,593 | 43 | $0 (2024) |
| Ascendis Pharma Inc | $7,113 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,795 | 263 | Lilly USA, LLC ($78,545) |
| 2023 | $116,485 | 281 | Lilly USA, LLC ($80,147) |
| 2022 | $104,473 | 274 | Lilly USA, LLC ($64,094) |
| 2021 | $96,646 | 277 | Novo Nordisk Inc ($38,180) |
| 2020 | $95,187 | 265 | Lilly USA, LLC ($33,765) |
| 2019 | $162,621 | 399 | Lilly USA, LLC ($76,249) |
| 2018 | $152,079 | 358 | SANOFI-AVENTIS U.S. LLC ($54,606) |
| 2017 | $147,426 | 345 | SANOFI-AVENTIS U.S. LLC ($80,321) |
All Payment Transactions
2,462 individual payment records from CMS Open Payments — Page 1 of 99
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Automated insulin delivery system | ||||||
| 12/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Diabetes Care | ||||||
| 12/18/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/17/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $15.99 | General |
| Category: Endocrinology | ||||||
| 12/12/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 12/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $24.47 | General |
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $1,890.00 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $10.72 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | IBSA Pharma Inc. | Tirosint (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Endocrinology | ||||||
| 12/02/2024 | IBSA Pharma Inc. | Tirosint (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Endocrinology | ||||||
| 12/02/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Biological | ||||||
| 11/21/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Endocrinology | ||||||
| 11/18/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $34.21 | General |
| 11/14/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/11/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/06/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Biological | ||||||
| 10/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $7.91 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Obesity | ||||||
| 10/24/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $28.99 | General |
| Category: Durable Pump | ||||||
| 10/22/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $20.80 | General |
| 10/17/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS-AWARD-PEDS- ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY | Eli Lilly and Company | $1,259 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 2,573 | 3,534 | $545,201 | $314,098 |
| 2022 | 15 | 2,226 | 3,814 | $456,012 | $267,767 |
| 2021 | 23 | 3,167 | 7,976 | $721,354 | $436,226 |
| 2020 | 19 | 3,220 | 10,467 | $749,642 | $397,304 |
Total Patients
11,186
Total Services
25,791
Medicare Billing
$1.4M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 568 | 953 | $176,305 | $122,369 | 69.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 771 | 1,106 | $150,416 | $96,592 | 64.2% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 493 | 509 | $86,530 | $37,847 | 43.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 168 | 168 | $42,000 | $19,632 | 46.7% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 83 | 89 | $31,150 | $8,850 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $15,544 | $8,584 | 55.2% |
| 88172 | Evaluation of fine needle aspirate | Office | 2023 | 80 | 204 | $15,862 | $8,578 | 54.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 87 | 168 | $10,920 | $4,413 | 40.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 104 | 104 | $7,280 | $3,501 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 22 | $2,002 | $1,412 | 70.5% |
| 10006 | Fine needle aspiration biopsy using ultrasound guidance, each additional growth | Office | 2023 | 23 | 23 | $4,600 | $1,100 | 23.9% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 93 | 104 | $2,080 | $980.56 | 47.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 12 | 12 | $372.00 | $195.03 | 52.4% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 12 | 14 | $140.00 | $44.94 | 32.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 242 | 1,470 | $95,860 | $67,425 | 70.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 278 | 323 | $59,755 | $42,598 | 71.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 485 | 508 | $86,360 | $38,400 | 44.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 331 | 375 | $51,000 | $34,716 | 68.1% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 158 | 191 | $25,222 | $18,795 | 74.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 116 | 116 | $31,088 | $18,740 | 60.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 142 | 142 | $35,500 | $16,341 | 46.0% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2022 | 86 | 93 | $32,550 | $10,033 | 30.8% |
| 88172 | Evaluation of fine needle aspirate | Office | 2022 | 83 | 218 | $16,786 | $9,096 | 54.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 118 | 169 | $8,965 | $6,106 | 68.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 56 | 71 | $4,615 | $1,898 | 41.1% |
About Dr. Lee Metchick, MD
Dr. Lee Metchick, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Deland, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407851801.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lee Metchick, MD has received a total of $972,713 in payments from pharmaceutical and medical device companies, with $97,795 received in 2024. These payments were reported across 2,462 transactions from 69 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($817,018).
As a Medicare-enrolled provider, Metchick has provided services to 11,186 Medicare beneficiaries, totaling 25,791 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Deland, FL
- Active Since 06/14/2005
- Last Updated 06/12/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1407851801
Products in Payments
- MOUNJARO (Drug) $197,266
- TRULICITY (Drug) $181,477
- SOLIQUA (Drug) $78,873
- Ozempic (Drug) $76,410
- TOUJEO (Drug) $69,950
- RYBELSUS (Drug) $43,106
- INVOKANA (Drug) $37,768
- Tresiba (Drug) $33,284
- t-slim insulin pump (Device) $28,524
- Korlym (Drug) $23,891
- RECORLEV (Drug) $22,400
- STEGLATRO (Drug) $17,232
- SOLIQUA 100/33 (Drug) $15,927
- Rybelsus (Drug) $15,712
- SOLIQUA 100/33 (Biological) $14,306
- Victoza (Drug) $12,168
- TOUJEO (Biological) $11,705
- t:slim X2 insulin pump (Device) $9,719
- Xultophy 100/3.6 (Drug) $8,989
- Tirosint (Drug) $8,470
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.